Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.68 |
| ▸ | CA12 | O43570 | 3/20 | 0.68 |
| ▸ | CA1 | P00915 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA6 | P23280 | 3/20 | 0.68 |
| ▸ | CA5A | P35218 | 3/20 | 0.68 |
| ▸ | CA7 | P43166 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.68 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 9/20 | 0.61 |
| ▸ | AQP1 | P29972 | 1/20 | 0.56 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229569 | 0.91 | CA12 (0.66) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL229243 | 0.90 | CA1 (0.74) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL4422550 | 0.89 | CA12 (0.68) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL4017488 | 0.89 | CISD1 (0.73) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL4412903 | 0.89 | CISD1 (0.76) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL22971174 | 0.88 | CA12 (0.67) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL2949798 | 0.87 | CA12 (0.76) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL230392 | 0.86 | APP (0.79) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL4017062 | 0.86 | CA12 (0.67) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL12418669 | 0.86 | CISD1 (0.69) | CISD1CA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-05-03 | — | — | US | claimed |
| EP-1874286-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA INC (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1874286-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | Neurotherapeutics Pharma LLC (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006110187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-10-19 | — | — | WO | claimed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | claimed |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3004353-B1 | BUMETANIDE FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | B & A THERAPEUTICS INMED (FR) | 2019-04-10 | — | — | EP | disclosed |
| US-10201507-B2 | Modulators of intracellular chloride concentration for treating fragile X syndrome | NEUROCHLORE (FR) | 2019-02-12 | — | — | US | disclosed |
| US-9974763-B2 | Modulators of intracellular chloride concentration for treating neurodegenerative diseases with Parkinsonian Syndromes | B&A THERAPEUTICS (FR) | 2018-05-22 | — | — | US | disclosed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1874286-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | Neurotherapeutics Pharma LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006110187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | PDE6C, AGER, PDE6A | CISD1 1905/4885CA12 3912/4885CA1 3247/4885 |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CISD1 3650/4885CA12 1338/4885CA1 988/4885 |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | SLC1A2, SLC18A2, GRIN2C | CISD1 3009/4885CA12 1092/4885CA1 490/4885 |
| US-10201507-B2 | Modulators of intracellular chloride concentration for treating fragile X syndrome | SLC8B1, SLC6A1, SLC8A1 | CISD1 1374/4885CA12 4639/4885CA1 3796/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CISD1 3650/4885CA12 1338/4885CA1 988/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CISD1 3822/4885CA12 1049/4885CA1 701/4885 |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | AQP4, AVPR2, AQP1 | CISD1 2281/4885CA12 1656/4885CA1 559/4885 |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | SLC1A2, SLC18A2, GRIN2C | CISD1 3009/4885CA12 1092/4885CA1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.